TABLE 1.

Incidence of CIP.

Study author	Numbers of		Tumor type	ICIs	Incidence of
	Trials	Patients			All grade	Grade 3/4	Pneumonitis-related death
Nishino et al. (6)	20	4,496	Melanoma, NSCLC, RCC, etc.	Nivolumab, pembrolizumab, and ipilimumab	2.7%	0.8%	0.2–2.3%
Abdel-Rahmen et al. (8)	11	6,671	Melanoma, NSCLC, RCC, prostate cancer	Nivolumab, pembrolizumab, and ipilimumab	1.3–11%	0.3–2.0%	–
Costa et al. (9)	9	5,353	Melanoma, NSCLC, RCC, etc.	Nivolumab, pembrolizumab, and ipilimumab	2.65%	–	–
Nishijima et al. (10)	7	3,450	Melanoma, NSCLC	Nivolumab, pembrolizumab, and atezolizumab	3.4%	1.3%	–
Delaunay et al. (11)	–	1,826	Melanoma, NSCLC	CTLA-4, PD-1, and PD-L1 inhibitors	3.5%	1.26%	0.33%
Naidoo et al. (12)	–	915	Melanoma, NSCLC, RCC, etc.	CTLA-4, PD-1, and PD-L1 inhibitors	4.7%	1.2%	0.1%

CIP, checkpoint inhibitor pneumonitis; ICIs, immune checkpoint inhibitors; NSCLC, non-small-cell lung cancer; RCC, renal cell carcinoma; CTLA-4, cytotoxic T lymphocyte-associated protein 4; PD-1, programmed cell death protein 1; and PD-L1, programmed cell death-ligand 1.